Potassium chloride

Generic Name: Potassium chloride

Brand Names: Bi-peglyte, Bss, Bss Ophthalmic Solution, Cardioplegic, Citrasate, Colyte, Dextrose and Electrolyte No. 75, Diphen, Eye Stream, Gavilyte-C, Gavilyte-G, Gavilyte-H and Bisacodyl, Gavilyte-N, Glycerolyte 57, Golytely, H.E.L.P.bicel, Hemosate Ultra, Ionosol-MB, Isolyte P, Isolyte S, Isolyte S pH 7.4, Isoplate, K 45, K-tab, Klor-con, Lactated Ringers, Moviprep, Naturalyte, Normosol-R, Nulytely, Nxstage Pureflow, Olimel, Peglyte, Periolimel, Phoxillum, Physiolyte, Physiosol, Plasma-lyte, Plasma-lyte 148, Plasma-lyte 148 In 5 % Dextrose, Plasma-lyte R, Plasmalyte A, Plegisol, Plenvu, Pokonza, Prismasol, Procalamine 3, Ringers, Selectbag One, Suflave, Tis-U-sol

Drug Type: Small Molecule

Chemical Formula: ClK

CAS Number: 7447-40-7

Unique Ingredient Identifier: 660YQ98I10

Background: A white crystal or crystalline powder used as an electrolyte replenisher, in the treatment of hypokalemia, in buffer solutions, and in fertilizers and explosives.

The FDA withdrew its approval for the use of all solid oral dosage form drug products containing potassium chloride that supply 100 mg or more of potassium per dosage unit, except for controlled-release dosage forms and those products formulated for preparation of solution prior to ingestion.

Indication: For use as an electrolyte replenisher and in the treatment of hypokalemia.

Associated Conditions: Dehydration, Dry Mouth, Hypokalemia, Hypotonic Dehydration, Hypovolaemia, Isotonic Dehydration, Markedly Reduced Food Intake, Metabolic Acidosis, Hypodermoclysis, Mild Metabolic acidosis, Mild, moderate Metabolic Acidosis, Ocular edema

Associated Therapies: Acid- Base Balance, Bowel preparation therapy, Electrolyte replacement, Fluid replacement therapy, Haemofiltration, Hemodialysis Treatment, Parenteral Nutrition, Parenteral rehydration therapy, Plasma Volume Replacement, Urine alkalinization therapy, Fluid and electrolyte maintenance therapy

Clinical Trials

Hypertonic Saline in Posterior Spinal Fusion

Phase 2

Not yet recruiting

Conditions: Scoliosis Idiopathic
Scoliosis;Congenital

Interventions: Drug: buffered 2% hypertonic saline
Drug: Normosol-R

First Posted Date: 2025-02-12

Last Posted Date: 2025-05-11

Lead Sponsor: Joseph D. Tobias

Target Recruit Count: 75

Registration Number: NCT06822374

Locations: 🇺🇸
Nationwide Children's, Columbus, Ohio, United States

Bowel Preparation for Colonoscopy Among Individuals With Crohn's and Ulcerative Colitis Disease.

Phase 4

Recruiting

Conditions: Crohn Disease
Ulcerative Colitis

Interventions: Drug: KleanLyte
Drug: Bi-PegLyte

First Posted Date: 2024-03-07

Last Posted Date: 2025-01-08

Lead Sponsor: University of Manitoba

Target Recruit Count: 418

Registration Number: NCT06298461

Locations: 🇨🇦
University of Manitoba, Winnipeg, Manitoba, Canada

The Evaluation of Balanced Salt Solution During Cataract Surgery

Phase 4

Active, not recruiting

Conditions: Cataract
Fuchs Dystrophy

Interventions: Drug: BSS Plus
Drug: BSS

First Posted Date: 2023-05-11

Last Posted Date: 2024-12-16

Lead Sponsor: Adam Fedyk, MD, FACS

Target Recruit Count: 27

Registration Number: NCT05853978

Locations: 🇺🇸
St. Louis Eye Institute, Town And Country, Missouri, United States

Aggressive Intravenous Hydration With Lactated Ringer's Solution for Prevention of Post-ESWL Pancreatitis

Not Applicable

Completed

Conditions: Pancreatitis, Chronic
Pancreatic Duct Stone

Interventions: Drug: Lactated ringers solution
Drug: normal saline

First Posted Date: 2023-03-16

Last Posted Date: 2025-03-28

Lead Sponsor: Changhai Hospital

Target Recruit Count: 1066

Registration Number: NCT05772234

Locations: 🇨🇳
Changhai Hospital, Shanghai, Shanghai, China

Balanced Multi-Electrolyte Solution Versus Saline Trial for Diabetic KetoAcidosis

Phase 3

Not yet recruiting

Conditions: Diabetic Ketoacidosis

Interventions: Drug: 0.9% sodium chloride
Drug: Plasma-Lyte 148

First Posted Date: 2023-03-02

Last Posted Date: 2024-01-18

Lead Sponsor: The George Institute

Target Recruit Count: 680

Registration Number: NCT05752279

Locations: 🇦🇺
Royal North Shore Hospital, St Leonards, New South Wales, Australia
🇦🇺
Redcliffe Hospital, Redcliffe, Queensland, Australia

A Trial to Compare Efficacy and Tolerability of Plenvu® and Picoprep® as Cleansing Agents Before Colonoscopy

Phase 4

Recruiting

Conditions: Colon Disease

Interventions: Drug: Picoprep
Drug: Plenvu

First Posted Date: 2022-06-28

Last Posted Date: 2024-11-19

Lead Sponsor: Aalborg University Hospital

Target Recruit Count: 400

Registration Number: NCT05436054

Locations: 🇩🇰
Aalborg University hospital, Aalborg, North Jutland, Denmark

Using Vasopressor Medication to Support Blood Pressure During Intubation Procedure

Phase 3

Completed

Conditions: Hypotension and Shock
Anesthesia Intubation Complication
Respiratory Failure
Intubation Complication
Hypotension on Induction

Interventions: Drug: Norepinephrine
Drug: Lactated Ringers, Intravenous
Drug: normal saline
Drug: Plasma-lyte

First Posted Date: 2022-05-02

Last Posted Date: 2024-07-15

Lead Sponsor: Wright State University

Target Recruit Count: 42

Registration Number: NCT05355974

Locations: 🇺🇸
Miami Valley Hospital Premier Health, Dayton, Ohio, United States

A Study Evaluating the Efficacy and Safety of IV L-Citrulline for the Prevention of Clinical Sequelae of Acute Lung Injury Induced by Cardiopulmonary Bypass in Pediatric Patients Undergoing Surgery for Congenital Heart Defects

Phase 3

Recruiting

Conditions: Ventricular Septal Defect
Atrioventricular Septal Defect
Primum Atrial Septal Defect

Interventions: Drug: Plasmalyte A
Drug: L-citrulline

First Posted Date: 2022-02-23

Last Posted Date: 2023-08-21

Lead Sponsor: Asklepion Pharmaceuticals, LLC

Target Recruit Count: 97

Registration Number: NCT05253209

Locations: 🇺🇸
Children's of Alabama, Birmingham, Alabama, United States
🇺🇸
Children's Hospital of Colorado, Aurora, Colorado, United States
🇺🇸
Heart Center, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States

and more 7 locations